Video

How PSA Has Impacted the Use of ADT in Prostate Cancer

Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      January 2023 AbbVie Inc. Company Confidential

      Related Videos
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      1 expert in this video
      Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
      1 expert in this video
      Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      1 expert in this video
      Comparing Trials Studying Treatment Intensification In mHSPC
      An Overview of the ARANOTE Trial
      An Overview of the ARANOTE Trial
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
      Related Content
      Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
      May 20th 2025

      Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

      Hannah Clarke
      The phase 3 study design will now be submitted for final review by the agency.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      SBRT may offer a safe alternative to CFRT after prostatectomy
      May 16th 2025

      SBRT may offer a safe alternative to CFRT after prostatectomy

      Hannah Clarke
      Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
      May 13th 2025

      MRI and focal therapy may enable men on AS to safely delay surgery or radiation

      Hannah Clarke
      Use of focal therapy was shown to prolong the duration of active surveillance.
      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
      May 6th 2025

      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

      Hannah Clarke
      Initial study results may be available as soon as the first half of 2026.
      © 2025 MJH Life Sciences

      All rights reserved.